Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
Abstract A reduced incidence of nonmelanoma skin cancer among users of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARb) has been reported. A similar effect is suggested for cutaneous melanoma. We aimed to investigate the possible association between use of ACEi...
Gespeichert in:
| Veröffentlicht in: | Cancer epidemiology 2009-11, Vol.33 (5), p.391-395 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 395 |
|---|---|
| container_issue | 5 |
| container_start_page | 391 |
| container_title | Cancer epidemiology |
| container_volume | 33 |
| creator | Koomen, E.R Herings, R.M.C Guchelaar, H.J Nijsten, T |
| description | Abstract A reduced incidence of nonmelanoma skin cancer among users of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARb) has been reported. A similar effect is suggested for cutaneous melanoma. We aimed to investigate the possible association between use of ACEi and ARb and the risk of cutaneous melanoma. A general population-based case control study with the PHARMO database, containing drug-dispensing records from community pharmacies and the national pathology database (PALGA) was conducted. Cases were patients with a primary cutaneous melanoma between January 1st 1991 and December 14th 2004, aged ≥18 years and having ≥3 years of follow-up prior to diagnosis. Finally, 1272 cases and 6520 matched controls were included. Multivariable conditional logistic regression showed no statistically significant associations between the incidence of melanoma and the use of ACEi (adjusted OR = 1.0, 95%CI: 0.8–1.3) or ARb (adjusted OR = 1.0, 95%CI: 0.7–1.5). Thus, in this study, the use of ACEi or ARb does not seem to protect against the development of cutaneous melanoma. However, we cannot exclude an association between ACEi and ARb exposure and an increased or decreased incidence of cutaneous melanoma. |
| doi_str_mv | 10.1016/j.canep.2009.10.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_746295771</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1877782109001349</els_id><sourcerecordid>746295771</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-d8f4d5ce557285bd63aa04f7de6a1fb3f18fc6199590b05ec285a8feae5359793</originalsourceid><addsrcrecordid>eNqFkk1v1DAQhi0Eoh_wC5BQJA6csozjOI4PIFUVBaQiDoDEzXLsSfE2sYOdVCy_Hqe7oqiXnmyPn3dGM-8Q8oLChgJt3mw3RnucNhWAzJENAH9EjmkrRCla9uPxv3tFj8hJSluApqGUPyVHVLaykVQek_EzDtqHURfOG2fRGyy0twX-nkJaIhZzyO8rF2b0yfnSBH-DcXb-qkD_Zzdi1v10nZtDTLfC_-AiosEp_xTdEMw1xvSMPOn1kPD54Twl3y_efzv_WF5--fDp_OyyNLVgc2nbvrbcIOeianlnG6Y11L2w2Gjad6ynbW8aKiWX0AFHkynd9qiRMy6FZKfk9T7vFMOvBdOsRpcMDrlVDEtSom4qyYWgD5Ospnlq1Uq-ukduwxJ9bkNRYFWuKyrIFNtTJoaUIvZqim7UcZchtdqmturWNrXatgazbVn18pB76Ua0d5qDTxl4uwcwT-3GYVTJuNUs6_KQZ2WDe6DAu3t6MzjvjB6ucYfprhOVKgXq67o56-KABKCsluwvf4vAng</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1032597720</pqid></control><display><type>article</type><title>Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Koomen, E.R ; Herings, R.M.C ; Guchelaar, H.J ; Nijsten, T</creator><creatorcontrib>Koomen, E.R ; Herings, R.M.C ; Guchelaar, H.J ; Nijsten, T</creatorcontrib><description>Abstract A reduced incidence of nonmelanoma skin cancer among users of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARb) has been reported. A similar effect is suggested for cutaneous melanoma. We aimed to investigate the possible association between use of ACEi and ARb and the risk of cutaneous melanoma. A general population-based case control study with the PHARMO database, containing drug-dispensing records from community pharmacies and the national pathology database (PALGA) was conducted. Cases were patients with a primary cutaneous melanoma between January 1st 1991 and December 14th 2004, aged ≥18 years and having ≥3 years of follow-up prior to diagnosis. Finally, 1272 cases and 6520 matched controls were included. Multivariable conditional logistic regression showed no statistically significant associations between the incidence of melanoma and the use of ACEi (adjusted OR = 1.0, 95%CI: 0.8–1.3) or ARb (adjusted OR = 1.0, 95%CI: 0.7–1.5). Thus, in this study, the use of ACEi or ARb does not seem to protect against the development of cutaneous melanoma. However, we cannot exclude an association between ACEi and ARb exposure and an increased or decreased incidence of cutaneous melanoma.</description><identifier>ISSN: 1877-7821</identifier><identifier>EISSN: 1877-783X</identifier><identifier>DOI: 10.1016/j.canep.2009.10.005</identifier><identifier>PMID: 19896919</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>ACE inhibitors ; Adolescent ; Adult ; Aged ; Angiotensin II type 1 receptor Antagonists ; Angiotensin II Type 1 Receptor Blockers - pharmacology ; Angiotensin-converting enzyme inhibitors ; Angiotensin-Converting Enzyme Inhibitors - pharmacology ; Cancer ; Epidemiology ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Incidence ; Internal Medicine ; Male ; Melanoma ; Melanoma - epidemiology ; Middle Aged ; Skin Neoplasms - epidemiology ; Young Adult</subject><ispartof>Cancer epidemiology, 2009-11, Vol.33 (5), p.391-395</ispartof><rights>Elsevier Ltd</rights><rights>2009 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-d8f4d5ce557285bd63aa04f7de6a1fb3f18fc6199590b05ec285a8feae5359793</citedby><cites>FETCH-LOGICAL-c473t-d8f4d5ce557285bd63aa04f7de6a1fb3f18fc6199590b05ec285a8feae5359793</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1032597720?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>315,782,786,3554,27933,27934,46004,64394,64396,64398,72478</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19896919$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koomen, E.R</creatorcontrib><creatorcontrib>Herings, R.M.C</creatorcontrib><creatorcontrib>Guchelaar, H.J</creatorcontrib><creatorcontrib>Nijsten, T</creatorcontrib><title>Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers</title><title>Cancer epidemiology</title><addtitle>Cancer Epidemiol</addtitle><description>Abstract A reduced incidence of nonmelanoma skin cancer among users of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARb) has been reported. A similar effect is suggested for cutaneous melanoma. We aimed to investigate the possible association between use of ACEi and ARb and the risk of cutaneous melanoma. A general population-based case control study with the PHARMO database, containing drug-dispensing records from community pharmacies and the national pathology database (PALGA) was conducted. Cases were patients with a primary cutaneous melanoma between January 1st 1991 and December 14th 2004, aged ≥18 years and having ≥3 years of follow-up prior to diagnosis. Finally, 1272 cases and 6520 matched controls were included. Multivariable conditional logistic regression showed no statistically significant associations between the incidence of melanoma and the use of ACEi (adjusted OR = 1.0, 95%CI: 0.8–1.3) or ARb (adjusted OR = 1.0, 95%CI: 0.7–1.5). Thus, in this study, the use of ACEi or ARb does not seem to protect against the development of cutaneous melanoma. However, we cannot exclude an association between ACEi and ARb exposure and an increased or decreased incidence of cutaneous melanoma.</description><subject>ACE inhibitors</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Angiotensin II type 1 receptor Antagonists</subject><subject>Angiotensin II Type 1 Receptor Blockers - pharmacology</subject><subject>Angiotensin-converting enzyme inhibitors</subject><subject>Angiotensin-Converting Enzyme Inhibitors - pharmacology</subject><subject>Cancer</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Incidence</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Melanoma</subject><subject>Melanoma - epidemiology</subject><subject>Middle Aged</subject><subject>Skin Neoplasms - epidemiology</subject><subject>Young Adult</subject><issn>1877-7821</issn><issn>1877-783X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkk1v1DAQhi0Eoh_wC5BQJA6csozjOI4PIFUVBaQiDoDEzXLsSfE2sYOdVCy_Hqe7oqiXnmyPn3dGM-8Q8oLChgJt3mw3RnucNhWAzJENAH9EjmkrRCla9uPxv3tFj8hJSluApqGUPyVHVLaykVQek_EzDtqHURfOG2fRGyy0twX-nkJaIhZzyO8rF2b0yfnSBH-DcXb-qkD_Zzdi1v10nZtDTLfC_-AiosEp_xTdEMw1xvSMPOn1kPD54Twl3y_efzv_WF5--fDp_OyyNLVgc2nbvrbcIOeianlnG6Y11L2w2Gjad6ynbW8aKiWX0AFHkynd9qiRMy6FZKfk9T7vFMOvBdOsRpcMDrlVDEtSom4qyYWgD5Ospnlq1Uq-ukduwxJ9bkNRYFWuKyrIFNtTJoaUIvZqim7UcZchtdqmturWNrXatgazbVn18pB76Ua0d5qDTxl4uwcwT-3GYVTJuNUs6_KQZ2WDe6DAu3t6MzjvjB6ucYfprhOVKgXq67o56-KABKCsluwvf4vAng</recordid><startdate>20091101</startdate><enddate>20091101</enddate><creator>Koomen, E.R</creator><creator>Herings, R.M.C</creator><creator>Guchelaar, H.J</creator><creator>Nijsten, T</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>7U1</scope><scope>7U2</scope><scope>C1K</scope></search><sort><creationdate>20091101</creationdate><title>Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers</title><author>Koomen, E.R ; Herings, R.M.C ; Guchelaar, H.J ; Nijsten, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-d8f4d5ce557285bd63aa04f7de6a1fb3f18fc6199590b05ec285a8feae5359793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>ACE inhibitors</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Angiotensin II type 1 receptor Antagonists</topic><topic>Angiotensin II Type 1 Receptor Blockers - pharmacology</topic><topic>Angiotensin-converting enzyme inhibitors</topic><topic>Angiotensin-Converting Enzyme Inhibitors - pharmacology</topic><topic>Cancer</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Incidence</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Melanoma</topic><topic>Melanoma - epidemiology</topic><topic>Middle Aged</topic><topic>Skin Neoplasms - epidemiology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koomen, E.R</creatorcontrib><creatorcontrib>Herings, R.M.C</creatorcontrib><creatorcontrib>Guchelaar, H.J</creatorcontrib><creatorcontrib>Nijsten, T</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Cancer epidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koomen, E.R</au><au>Herings, R.M.C</au><au>Guchelaar, H.J</au><au>Nijsten, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers</atitle><jtitle>Cancer epidemiology</jtitle><addtitle>Cancer Epidemiol</addtitle><date>2009-11-01</date><risdate>2009</risdate><volume>33</volume><issue>5</issue><spage>391</spage><epage>395</epage><pages>391-395</pages><issn>1877-7821</issn><eissn>1877-783X</eissn><abstract>Abstract A reduced incidence of nonmelanoma skin cancer among users of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARb) has been reported. A similar effect is suggested for cutaneous melanoma. We aimed to investigate the possible association between use of ACEi and ARb and the risk of cutaneous melanoma. A general population-based case control study with the PHARMO database, containing drug-dispensing records from community pharmacies and the national pathology database (PALGA) was conducted. Cases were patients with a primary cutaneous melanoma between January 1st 1991 and December 14th 2004, aged ≥18 years and having ≥3 years of follow-up prior to diagnosis. Finally, 1272 cases and 6520 matched controls were included. Multivariable conditional logistic regression showed no statistically significant associations between the incidence of melanoma and the use of ACEi (adjusted OR = 1.0, 95%CI: 0.8–1.3) or ARb (adjusted OR = 1.0, 95%CI: 0.7–1.5). Thus, in this study, the use of ACEi or ARb does not seem to protect against the development of cutaneous melanoma. However, we cannot exclude an association between ACEi and ARb exposure and an increased or decreased incidence of cutaneous melanoma.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>19896919</pmid><doi>10.1016/j.canep.2009.10.005</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1877-7821 |
| ispartof | Cancer epidemiology, 2009-11, Vol.33 (5), p.391-395 |
| issn | 1877-7821 1877-783X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_746295771 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | ACE inhibitors Adolescent Adult Aged Angiotensin II type 1 receptor Antagonists Angiotensin II Type 1 Receptor Blockers - pharmacology Angiotensin-converting enzyme inhibitors Angiotensin-Converting Enzyme Inhibitors - pharmacology Cancer Epidemiology Female Hematology, Oncology and Palliative Medicine Humans Incidence Internal Medicine Male Melanoma Melanoma - epidemiology Middle Aged Skin Neoplasms - epidemiology Young Adult |
| title | Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-02T20%3A41%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Melanoma%20incidence%20and%20exposure%20to%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers&rft.jtitle=Cancer%20epidemiology&rft.au=Koomen,%20E.R&rft.date=2009-11-01&rft.volume=33&rft.issue=5&rft.spage=391&rft.epage=395&rft.pages=391-395&rft.issn=1877-7821&rft.eissn=1877-783X&rft_id=info:doi/10.1016/j.canep.2009.10.005&rft_dat=%3Cproquest_cross%3E746295771%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1032597720&rft_id=info:pmid/19896919&rft_els_id=S1877782109001349&rfr_iscdi=true |